Sustained-Release Naltrexone Formulation for Adverse Effect Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The co-administration of immediate-release naltrexone with bupropion or fluoxetine results in an unexpectedly high incidence of adverse effects, exceeding the typical incidence of adverse effects associated with each medication alone, indicating a need for a formulation that reduces these adverse effects.
Innovation Solution
Development of a sustained-release naltrexone formulation that provides a reduced peak plasma concentration and extended release profile, thereby minimizing adverse effects when co-administered with bupropion or fluoxetine, and is effective in causing weight loss or inhibiting weight gain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immediate-release naltrexone is co-administered with bupropion or fluoxetine, then the opioid antagonist effect is achieved, but the incidence of adverse effects increases unexpectedly
Solution Approach 1:
The patent applies dynamics by transitioning from a static immediate-release formulation to a dynamic sustained-release formulation that adapts drug delivery over time. The sustained-release naltrexone formulation releases the active ingredient gradually, creating a dynamic pharmacokinetic profile that maintains therapeutic levels while avoiding peak concentration-related adverse effects when co-administered with bupropion or fluoxetine.
Solution Approach 2:
The patent changes the pharmacokinetic parameters of naltrexone by developing a sustained-release formulation that modifies the release rate, peak concentration timing, and duration of action. This parameter change reduces the Cmax (peak plasma concentration) and extends the half-life, thereby decreasing the incidence of adverse effects while maintaining the opioid antagonist effect during co-administration with bupropion or fluoxetine.
2Object-affected harmful factors
If sustained-release naltrexone formulation is used, then adverse effects are reduced, but the peak plasma concentration needs to be controlled at 80% or less of immediate-release
Solution Approach 1:
The patent employs feedback by establishing a target pharmacokinetic profile with specific constraints (Cmax ≤ 80% of immediate-release, AUClast between 80-125% of immediate-release) and using these targets to guide the formulation development. The sustained-release formulation is designed and optimized based on feedback from pharmacokinetic studies to ensure it meets the specified parameters for reducing adverse effects while maintaining efficacy.
Solution Approach 2:
The patent precisely controls pharmacokinetic parameters through the sustained-release formulation design. By modifying the release rate and formulation characteristics, the patent achieves the desired parameter range (Cmax ≤ 80%, AUClast 80-125%) that balances adverse effect reduction with therapeutic efficacy, demonstrating precise parameter control in the manufacturing process.
3Reliability
If naltrexone is used for weight management, then weight loss or weight gain inhibition is achieved, but the formulation must maintain efficacy while reducing adverse effects
Solution Approach 1:
The patent uses dynamics to maintain weight management efficacy while reducing adverse effects through the sustained-release formulation. The dynamic release profile ensures continuous presence of naltrexone at therapeutic levels needed for weight management, while avoiding the sharp peaks that cause adverse effects. This dynamic approach allows the formulation to maintain efficacy throughout the dosing interval.
Solution Approach 2:
The sustained-release formulation provides continuous action of naltrexone for weight management by maintaining steady plasma concentrations over an extended period. This continuous presence of the active ingredient ensures ongoing efficacy for weight loss or weight gain inhibition while avoiding the intermittent high peaks associated with immediate-release formulations that lead to adverse effects.
Data Source
AI summary
A sustained-release oral dosage form of naltrexone or a pharmaceutically acceptable salt thereof is provided. The oral dosage form may be administered with another compound. Administration of the oral dosage form may reduce a side effect, which may be a side effect at least partially attributable to a weight-loss treatment. The oral dosage form may be administered to treat a weight-loss condition.